Zhao Dan-Dan, Zhang Xiao-Qing, Yang Tao, Liu Qian, Lan Zhen-Zhen, Yang Xiao-Li, Qu Hui-Yan, Zhou Hua
Cardiovascular Research Institute, Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai 201203, China.
Cardiovascular Department of Traditional Chinese Medicine, Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai 201203, China.
Evid Based Complement Alternat Med. 2021 Nov 25;2021:6645878. doi: 10.1155/2021/6645878. eCollection 2021.
Tingli Dazao Xiefei decoction (TDXD) has been shown to have a therapeutic effect on heart failure (HF). Nevertheless, its molecular mechanism for treating HF is still unclear.
TDXD and HF targets were collected from the databases, and protein-protein interaction (PPI) analysis and enrichment analysis were performed on the overlapping targets. Then, AutoDock was employed for molecular docking. Finally, we used the left anterior descending coronary artery (LAD) ligation to induce HF model rats for in vivo experiments and verified the effect and mechanism of TDXD on HF.
Network pharmacological analysis showed that the main active components of TDXD in treating HF were quercetin, kaempferol, beta-carotene, isorhamnetin, and beta-sitosterol, and the core targets were IL-6, VEGFA, TNF, AKT1, and MAPK1. Multiple gene functions and signaling pathways were obtained by enrichment analysis, among which inflammation-related, PI3K/Akt, and MAPK signaling pathways were closely related to HF. Furthermore, the molecular docking results showed that the core targets had good binding ability with the main active components. Animal experiments showed that TDXD could effectively improve left ventricular ejection fraction (EF) and left ventricular fractional shortening (FS), decrease left ventricular internal diastolic diameter (LVIDd) and left ventricular internal systolic diameter (LVIDs), reduce the area of myocardial fibrosis, and decrease serum BNP, LDH, CK-MB, IL-6, IL-1, and TNF- levels in HF rats. Meanwhile, TDXD could upregulate the expression of Bcl-2, downregulate the expression of Bax, and reduce cardiomyocyte apoptosis. At the same time, it was verified that TDXD could significantly decrease the expression of PI3K, P-Akt, and P-MAPK. Captopril showed similar effects.
Combining network pharmacological analysis and experimental validation, this study verified that TDXD could improve cardiac function and protect against cardiac injury by inhibiting the activation of PI3K/Akt and MAPK signaling pathways.
葶苈大枣泻肺汤(TDXD)已被证明对心力衰竭(HF)具有治疗作用。然而,其治疗HF的分子机制仍不清楚。
从数据库中收集TDXD和HF靶点,并对重叠靶点进行蛋白质-蛋白质相互作用(PPI)分析和富集分析。然后,采用AutoDock进行分子对接。最后,我们采用左冠状动脉前降支(LAD)结扎法诱导HF模型大鼠进行体内实验,验证TDXD对HF的作用及机制。
网络药理学分析表明,TDXD治疗HF的主要活性成分是槲皮素、山奈酚、β-胡萝卜素、异鼠李素和β-谷甾醇,核心靶点是IL-6、VEGFA、TNF、AKT1和MAPK1。通过富集分析获得了多个基因功能和信号通路,其中炎症相关、PI3K/Akt和MAPK信号通路与HF密切相关。此外,分子对接结果表明,核心靶点与主要活性成分具有良好的结合能力。动物实验表明,TDXD可有效提高左心室射血分数(EF)和左心室缩短分数(FS),降低左心室内径舒张末期(LVIDd)和左心室内径收缩末期(LVIDs),减少心肌纤维化面积,并降低HF大鼠血清BNP、LDH、CK-MB、IL-6、IL-1和TNF-水平。同时,TDXD可上调Bcl-2表达,下调Bax表达,减少心肌细胞凋亡。同时,验证了TDXD可显著降低PI3K、P-Akt和P-MAPK的表达。卡托普利显示出类似的效果。
本研究结合网络药理学分析和实验验证,证实TDXD可通过抑制PI3K/Akt和MAPK信号通路的激活来改善心脏功能并预防心脏损伤。